The Pharmacogenomics Aspects of Drugs Used in COVID-19 Treatment

Authors

  • Gazala Afreen Khan Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, United Arab Emirates
  • Yomna Rabba Elsayed Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, United Arab Emirates
  • Marwa Osama Said Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, United Arab Emirates

DOI:

https://doi.org/10.3329/jom.v23i1.57939

Keywords:

Pharmacogenomics, COVID-19

Abstract

The increase in mortality and morbidity related to the novel COVID-19 virus led researchers to work ondeveloping new therapies to destroy the virus. Numerous clinical trials have started to find drugs that willeffectively treat the signs and symptoms of the virus. This review aims to summarize the pharmacogenomicaspects of drugs such as hydroxychloroquine, chloroquine, azithromycin, remdesivir, favipiravir, ribavirin,lopinavir/ritonavir, darunavir/cobicistat, interferon beta-1b, tocilizumab, ruxolitinib, baricitinib, andcorticosteroids used in the treatment of this virus. The data will be collected from various websites such asPubMed, Lancet, WHO website, PharmGKB website, IDSA Guidelines on the treatment & management ofCOVID-19 Patients, the U.S. Food and Drug Administration (FDA) product labeling, and pharmacogenomicstables. Incomplete data exists related to the efficacy and safety of these drugs and healthcare providers arestruggling to make the right treatment choices. Drug-gene variants may alter the pharmacokinetics andsafety of some drugs and thus produce adverse drug reactions. Therefore, pharmacogenomics may helpdoctors decide the correct course of treatment by knowing the genetic makeup of an individual. This caneventually help to eliminate adverse drug reactions and reduce the mortality rate.

J MEDICINE 2022; 23: 61-76

Downloads

Download data is not yet available.
Abstract
39
PDF
49

Downloads

Published

2022-02-03

How to Cite

Khan, G. A. ., Elsayed, Y. R. ., & Said, M. O. . (2022). The Pharmacogenomics Aspects of Drugs Used in COVID-19 Treatment. Journal of Medicine, 23(1), 61–76. https://doi.org/10.3329/jom.v23i1.57939

Issue

Vol. 23 No. 1 (2022)

Section

Review Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).